Vaccination against pneumococcal infection in adults from risk groups

In Russia starting from 2014, adults from risk groups are vaccinated against pneumococcal infection in accordance with the vaccination calendar based on epidemic indications. However, data collected by the Epidemiological Surveillance for Vaccine Prevention do not allow to judge about the protection of adult population against pneumococcal disease, as there is no information on the coverage of risk groups.

The objective: to analyze the coverage of adult population from risk groups with vaccination against pneumococcal infection.

Subjects and methods. The number and groups of adults vaccinated against pneumococcal infection were provided by the executive authorities in charge of health care in the Russian Federation. Data for 4 years were collected (2015-2018). The information was received from 79 regions of the Russian Federation. Descriptive statistics methods were used to analyze the coverage in age and occupational risk groups and people with chronic diseases.

Results. The main groups of adults vaccinated against pneumococcal infection were the following: patients with chronic diseases (55%, including 27.5% of patients with chronic lung disease), conscripts (30%), various occupational risk groups (11%). The remaining risk groups accounted for less than 5% of vaccinations. The maximum coverage was achieved among adults with chronic lung disease (15.1%). Among patients with chronic non-pulmonary diseases, coverage was the following: patients with liver diseases – 4%, cardiovascular diseases – 3.8%, endocrine system – 2.8%, immunodeficiencies – 1%. In other groups of chronic patients, coverage was even lower. Among adults with occupational risk factors and staying in special conditions, the maximum vaccination coverage was achieved among conscripts (67.4%). Vaccination in other categories of occupational risk was performed in a small number of people; among health workers, it was 4.9%, among employees of educational organizations of open type (schools, kindergartens, etc.) it made 3.1%.

1. Briko N.I., Feldblyum I.V. The modern concept of vaccination development in Russia. Epidemiologiya i Vaktsionoprofilaktika, 2019, vol. 18, no. 5, pp. 4-13 (In Russ.) https://doi.org/10.31631/2073-3046-2019-18-5-4-13.

2. Briko N.I., Feldblyum I.V., Аlyeva M.Kh., Tsapkova N.N., Korshunov V.А., Kostenko N.А., Drapkina O.M. The draft national calendar for vaccination of adults in Russia. Profilakticheskaya Meditsina, 2018, vol. 21, no. 5, pp. 28-34. (In Russ.) https://doi.org/10.17116/profmed20182105128.

3. Use instructions for the medicinal product of Prevenar® 13 for medical purposes (13-valent pneumococcal polysaccharide conjugated adsorbed vaccine). Epub.(In Russ.) Available: http://grls.rosminzdrav.ru/grls.aspx?s=превенар&m=tn, Accessed 17.03.2020.

4. Use instructions for the medicinal product of Pnevmovaks® 23 for medical purposes (polyvalent pneumococcal vaccine). Epub. (In Russ.) Available:http://grls.rosminzdrav.ru/grls.aspx?s=%u043f%u043d%u0435%u0432%u043c%u043e%u0432%u0430%u043a%u0441&m=tn, Accessed 17.03.2020.

5. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. ISSN 0022-9040. Kardiologia, 2018, vol. 58 (S6). (In Russ.) doi: 10.18087/cardio. 2475.

6. Edict no. 125n by the Russian Ministry of Health as of 21.03.2014 On Approval the National Vaccination Calendar and Vaccination Calendar Based on Epidemic Indications. (In Russ.)

7. Rudakova А.V., Briko N.I., Lobzin Yu.V., Namazova-Baranova L.S., Drapkina O.M., Аvdeev S.N., Drozdova L.Yu., Ignatova G.L., Koroleva I.S., Korshunov V.А., Kostinov M.P. Cost-effectiveness of vaccination against pneumococcal infection of adults at risk within the federal and regional programs. Journal Infektologii, 2019, vol. 11, no. 4, pp. 6-18. (In Russ.) https://doi.org/10.22625/2072-6732-2019-11-4-6-18.

8. Chuchalin А.G., Briko N.I., Аvdeev S.N., Belevskiy А.S., Bilichenko T.N., Demko I.V., Drapkina O.M., Zhestkov А.V., Zaytsev А.А., Ignatova G.L., Kovalishena O.V., Korshunov V.А., Kostinov M.P., Mishlanov V.Yu., Sidorenko S.V., Trushenko N.V., Shubin I.V., Feldblyum I.V. Federal clinical guidelines for the vaccination against pneumococcal infection in adults. Pulmonoloiya, 2019, vol. 29, no. 1, pp. 19-34. (In Russ.) doi: 10.18093/0869-0189-2019-29-1-19-34.

9. Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am. J. Respir. Crit. Care Med., 2019, vol. 200, issue 7, pp. e45-e67. Epub. Available: https://www.atsjournals.org/doi/full/10.1164/rccm.201908-1581ST Accessed 17.03.2020.

10. Pneumococcal ACIP Vaccine Recommendations. Available: https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html Accessed 17.03.2020.

11. Shea K.M., Edelsberg J., Weycker D., Farkouh R.A., Strutton D.R., Pelton S. I. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect. Dis., 2014, vol. 1, no. 1, ofu024. doi: 10.1093/ofid/ofu024.